Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
06 December 2022 - 12:07AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF
FOREIGN PRIVATE ISSUER
PURSUANT TO SECTION 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of December, 2022
Commission File Number: 001-36815
Ascendis Pharma A/S
(Exact Name of Registrant as Specified in Its Charter)
Tuborg
Boulevard 12
DK-2900 Hellerup
Denmark
(Address of
principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form
20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
INCORPORATION BY REFERENCE
This report on
Form 6-K shall be deemed to be incorporated by reference into the registration statements on Form S-8 (Registration Numbers
333-228576, 333-203040, 333-210810, 333-211512,
333-213412, 333-214843, 333-216883, 333-254101 and
333-261550) and Form F-3 (Registration Numbers 333-209336, 333-211511, 333-216882, 333-223134,333-225284 and 333-256571) of Ascendis Pharma A/S (the
Company) (including any prospectuses forming a part of such registration statements) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or
furnished.
On December 5, 2022, the Company announced that the U.S. Food & Drug Administration has allowed the Company to initiate an expanded access
program for its investigational parathyroid hormone replacement therapy, TransCon PTH (palopegteriparatide), for adult patients with hypoparathyroidism.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
Ascendis Pharma A/S |
|
|
|
|
Date: December 5, 2022 |
|
|
|
By: |
|
/s/ Michael Wolff Jensen |
|
|
|
|
|
|
Michael Wolff Jensen |
|
|
|
|
|
|
Senior Vice President, Chief Legal Officer |
Ascendis Pharma AS (NASDAQ:ASND)
Historical Stock Chart
From Oct 2023 to Nov 2023
Ascendis Pharma AS (NASDAQ:ASND)
Historical Stock Chart
From Nov 2022 to Nov 2023